GCP
ALGS icon

GSA Capital Partners’s Aligos Therapeutics ALGS Stock Holding History

GSA Capital Partners’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-421
Closed -$12K – 1427
2022
Q3 		$12K Sell
421
-408
-49% -$13.5K ﹤0.01% 1457
2022
Q2 		$25K Buy
+829
New +$28.2K ﹤0.01% 1312

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GSA Capital Partners's ALGS Position: Q4 2022 in Review

GSA Capital Partners sold out of Aligos Therapeutics (ALGS) in Q4 2022, closing a stake of 421 shares — an estimated $12K sold.

GSA Capital Partners first reported a position in ALGS in Q2 2022 and held it in 2 quarters. The position peaked at $25K in Q2 2022. 38 funds tracked by Wall St. Rank hold ALGS as of Q4 2022.

  • GSA Capital Partners reported no remaining Aligos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • GSA Capital Partners sold 421 Aligos Therapeutics shares in Q4 2022, an estimated $12K.
  • GSA Capital Partners first reported a position in Aligos Therapeutics in Q2 2022 and held it in 2 quarters.
  • GSA Capital Partners's Aligos Therapeutics position peaked at $25K in Q2 2022.
  • 38 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.